Autologous T regulatory cell therapy - Tract Therapeutics

Drug Profile

Autologous T regulatory cell therapy - Tract Therapeutics

Alternative Names: Expanded Tregs - Tract Therapeutics; Treg adoptive cell transfer - Tract Therapeutics

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Tract Therapeutics
  • Developer Northwestern University; Tract Therapeutics
  • Class T lymphocyte cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal transplant rejection
  • Research Autoimmune disorders

Most Recent Events

  • 29 Jul 2016 TRACT Therapeutics plans to apply for orphan drug status in organ transplantation in
  • 29 Jul 2016 TRACT Therapeutics plans phase I trials for Liver transplant rejection and Inflammatory bowel disease
  • 29 Apr 2016 Tract therapeutics plans a phase II trial for Renal transplant rejection (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top